Thermo Fisher Scientific (TMO) Gains from Investment Securities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Gains from Investment Securities for 18 consecutive years, with -$88.0 million the latest figure, recorded in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$88.0 million, up 34.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$408.0 million (down 353.33% YoY), and the FY2025 annual result was -$455.0 million, down 5587.5% from the prior year.
• Gains from Investment Securities was -$88.0 million for Q1 2026 at Thermo Fisher Scientific, up from -$435.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $408.0 million in Q4 2023 and troughed at -$470.0 million in Q4 2022.
• Average Gains from Investment Securities over 5 years is -$66.7 million, with a median of -$88.0 million recorded in 2026.
• The widest YoY moves for Gains from Investment Securities: up 204.17% in 2022, down 23600.0% in 2022.
• Over 5 years, Gains from Investment Securities stood at -$470.0 million in 2022, then surged by 186.81% to $408.0 million in 2023, then tumbled by 39.71% to $246.0 million in 2024, then tumbled by 276.83% to -$435.0 million in 2025, then surged by 79.77% to -$88.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$88.0 million in Q1 2026, -$435.0 million in Q4 2025, and $178.0 million in Q3 2025.